imroz: isa-vrd vs vrd for transplant-ineligible newly diagnosed multiple myeloma
Published 2 weeks ago • 42 plays • Length 3:57Download video MP4
Download video MP3
Similar videos
-
12:37
isa-vrd vs vrd for transplant-ineligible patients with newly diagnosed multiple myeloma (imroz)
-
5:06
imroz- isarvd vs rvd in newly diagnosed transplant ineligible mm | thierry facon, md | eha 2024
-
4:24
isatuximab vrd or vcd in newly diagnosed transplant-ineligible myeloma
-
1:52
analyzing isatuximab in quadruplet combinations in transplant-ineligible multiple myeloma
-
5:34
asco 2024 phase 3 imroz results evaluating sarclisa (isatuximab) vrd in transplant-ineligible ndmm
-
4:04
the future of myeloma treatment and the possibility of cure
-
4:23
ifm 2018-02: ixazomib daratumumab in elderly frail patients with r/r multiple myeloma
-
5:39
identifying vulnerable patients with multiple myeloma
-
1:52
upfront asct for newly diagnosed multiple myeloma: double vs. single transplant
-
3:37
eha2024 |the imroz study
-
2:48
an overview of trials in progress in al amyloidosis: highlights from isa 2024
-
3:52
isatuximab with vrd in pts with newly diagnosed multiple myeloma non-eligible for transplant
-
5:34
asco 2024 top 5 sarclisa isatuximab vrd phase 3 imroz multiple myeloma questions
-
4:01
choosing between isatuximab & daratumumab in multiple myeloma
-
2:15
the management of multiple myeloma in 2021
-
0:52
differences in approaches to managing patients with multiple myeloma vs amyloidosis
-
2:12
ash 2023 | minimal residual disease (mrd) measurement in myeloma
-
2:30
daratumumab and isatuximab in the treatment of multiple myeloma
-
2:32
the safety and efficacy of isatuximab for r/r myeloma: insights from icaria-mm, ikema & candor
-
4:35
agmt mm 02: outcomes and time to best response in myeloma
-
4:30
ikema: kd vs isatuximab and kd in r/r myeloma
-
7:40
the evolving myeloma diagnosis criteria